These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 34170306)

  • 1. Comparison of COVID-19 Vaccine Approvals at the US Food and Drug Administration, European Medicines Agency, and Health Canada.
    Lythgoe MP; Middleton P
    JAMA Netw Open; 2021 Jun; 4(6):e2114531. PubMed ID: 34170306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Comparison of EMA and FDA Decisions for New Drug Marketing Applications 2014-2016: Concordance, Discordance, and Why.
    Kashoki M; Hanaizi Z; Yordanova S; Veselý R; Bouygues C; Llinares J; Kweder SL
    Clin Pharmacol Ther; 2020 Jan; 107(1):195-202. PubMed ID: 31306483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characteristics of Recent Generic Drug Approvals by the US Food and Drug Administration.
    Jiao K; Gupta R; Fox E; Kesselheim A; Ross JS
    JAMA Netw Open; 2019 Oct; 2(10):e1913029. PubMed ID: 31603482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Despite criticism of the FDA review process, new cancer drugs reach patients sooner in the United States than in Europe.
    Roberts SA; Allen JD; Sigal EV
    Health Aff (Millwood); 2011 Jul; 30(7):1375-81. PubMed ID: 21680577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparisons of Food and Drug Administration and European Medicines Agency risk management implementation for recent pharmaceutical approvals: report of the International Society for Pharmacoeconomics and outcomes research risk benefit management working group.
    Lis Y; Roberts MH; Kamble S; J Guo J; Raisch DW
    Value Health; 2012 Dec; 15(8):1108-18. PubMed ID: 23244814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FDA posts record number of drug approvals in 1996.
    Am J Health Syst Pharm; 1997 Mar; 54(5):494, 497-8. PubMed ID: 9066856
    [No Abstract]   [Full Text] [Related]  

  • 7. Has the COVID-19 Crisis Affected the Growth of United States Food and Drug Administration Drug Approvals? The Answer is Not Yet! A Time Series (Forecasting) Study.
    Daizadeh I
    Ther Innov Regul Sci; 2021 May; 55(3):553-557. PubMed ID: 33367967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transparency of Regulatory Data across the European Medicines Agency, Health Canada, and US Food and Drug Administration.
    Egilman AC; Kapczynski A; McCarthy ME; Luxkaranayagam AT; Morten CJ; Herder M; Wallach JD; Ross JS
    J Law Med Ethics; 2021; 49(3):456-485. PubMed ID: 34665102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Muddied messages about FDA.
    Miller HI
    Nat Biotechnol; 2003 Jul; 21(7):732-3. PubMed ID: 12833084
    [No Abstract]   [Full Text] [Related]  

  • 10. FDA authorizes first single-shot COVID-19 vaccine.
    Mullard A
    Nat Rev Drug Discov; 2021 Apr; 20(4):251. PubMed ID: 33707753
    [No Abstract]   [Full Text] [Related]  

  • 11. Being fair to participants in placebo-controlled COVID-19 vaccine trials.
    Dal-Ré R; Orenstein W; Caplan AL
    Nat Med; 2021 Jun; 27(6):938. PubMed ID: 33903751
    [No Abstract]   [Full Text] [Related]  

  • 12. Characteristics of non-randomised studies using comparisons with external controls submitted for regulatory approval in the USA and Europe: a systematic review.
    Goring S; Taylor A; Müller K; Li TJJ; Korol EE; Levy AR; Freemantle N
    BMJ Open; 2019 Feb; 9(2):e024895. PubMed ID: 30819708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between FDA and EMA expedited approval programs and therapeutic value of new medicines: retrospective cohort study.
    Hwang TJ; Ross JS; Vokinger KN; Kesselheim AS
    BMJ; 2020 Oct; 371():m3434. PubMed ID: 33028575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Registering medicines for low-income countries: how suitable are the stringent review procedures of the World Health Organisation, the US Food and Drug Administration and the European Medicines Agency?
    Doua JY; Van Geertruyden JP
    Trop Med Int Health; 2014 Jan; 19(1):23-36. PubMed ID: 24134396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Accelerating regulation in response to COVID-19.
    Bull World Health Organ; 2020 Aug; 98(8):514-515. PubMed ID: 32773895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulatory approval of pharmaceuticals without a randomised controlled study: analysis of EMA and FDA approvals 1999-2014.
    Hatswell AJ; Baio G; Berlin JA; Irs A; Freemantle N
    BMJ Open; 2016 Jun; 6(6):e011666. PubMed ID: 27363818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Time required for approval of new drugs in Canada, Australia, Sweden, the United Kingdom and the United States in 1996-1998.
    Rawson NS
    CMAJ; 2000 Feb; 162(4):501-4. PubMed ID: 10701383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. To what degree are review outcomes aligned for new active substances (NASs) between the European Medicines Agency and the US Food and Drug Administration? A comparison based on publicly available information for NASs initially approved in the time period 2014 to 2016.
    Kühler TC; Bujar M; McAuslane N; Liberti L
    BMJ Open; 2019 Nov; 9(11):e028677. PubMed ID: 31772082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing tumor-related signs and symptoms to support cancer drug approval.
    Williams G; Pazdur R; Temple R
    J Biopharm Stat; 2004 Feb; 14(1):5-21. PubMed ID: 15027497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Canadian, European and United States new drug approval times now relatively similar.
    Rawson NSB
    Regul Toxicol Pharmacol; 2018 Jul; 96():121-126. PubMed ID: 29730446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.